Francesca Ambrogio
Overview
Explore the profile of Francesca Ambrogio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ambrogio F, Foti C, Noviello S, Cazzato G, Meduri A, Marasco C, et al.
Diagnostics (Basel)
. 2025 Mar;
15(5).
PMID: 40075770
This report discusses a female patient with longstanding discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE), refractory to multiple immunosuppressive and biologic treatments. Upon presenting with infiltrated, hypertrophic plaques...
2.
De Marco A, Liguori G, Cafarchia C, Triggiano F, Ciccarese G, Poli M, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004809
: Dermatophytosis due to () has spread worldwide, and the acquisition of new drug resistances is making this threat challenging to face. We report four cases of dermatophytosis caused by...
3.
Cazzato G, Piscazzi F, Filosa A, Colagrande A, Del Fiore P, Ambrogio F, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004764
Clear Cell Sarcoma (CCS) of soft tissue is a rare and highly malignant neoplasm primarily affecting young adults, often presenting in the deep soft tissues of the extremities. Despite morphological...
4.
Ambrogio F, Perillo T, Bonamonte D, De Marco A, Tirone B, Laface C, et al.
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004635
Selumetinib, a MEK1/2 inhibitor, is commonly used for treating neurofibromatosis type 1 (NF1) and is associated with cutaneous side effects such as paronychia and periungual granulomas. These complications can be...
5.
Mortato E, De Caro A, Schinzari L, Maniglio S, Laface C, Cazzato G, et al.
Dermatol Reports
. 2025 Feb;
PMID: 39969067
Cyclin-dependent kinase (CDK) 4/6 inhibitors, such as palbociclib, ribociclib, and abemaciclib, are widely used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor...
6.
Laface C, Fina E, Ricci A, Guven D, Ambrogio F, De Summa S, et al.
Expert Opin Biol Ther
. 2024 Nov;
24(12):1363-1374.
PMID: 39545466
Introduction: Recently, immunotherapy has offered new hope for treating biliary tract cancer (BTC). However, several issues are to be considered, including the lack of validated predictive biomarkers that could help...
7.
Meduri A, Tirone B, Lospalluti L, Ambrogio F, Cazzato G, Bellino M
Am J Dermatopathol
. 2024 Oct;
47(1):77-79.
PMID: 39481031
No abstract available.
8.
Caldarola G, Raimondi G, Samela T, Pinto L, Pampaloni F, Starace M, et al.
Front Public Health
. 2024 Sep;
12:1415334.
PMID: 39220459
Objective: The prevalence of anxiety and depression in patients diagnosed with Alopecia Areata (AA) is very high and this significant burden of psychological symptoms threatens the Health-Related Quality of Life...
9.
Cazzato G, Ambrogio F, Foti C, Ribatti D
Intern Emerg Med
. 2024 Jul;
20(1):309-311.
PMID: 39073477
No abstract available.
10.
Laface C, Ricci A, Vallarelli S, Ostuni C, Rizzo A, Ambrogio F, et al.
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39062979
Autotaxin (ATX) is a member of the ectonucleotide pyrophosphate/phosphodiesterase () family; it is encoded by the gene. ATX is a secreted glycoprotein and catalyzes the hydrolysis of lysophosphatidylcholine to lysophosphatidic...